RE:TFC-039 and Wanbang milestonesExciting post that matches my assessment. In contrast to Europe and the USA, reaching Phase II in the CFDA does not have any publicity effect. If SBM is really ahead of schedule, as Dr. Verrico claims, it is also obvious that you have already reached Phase III. If, in addition, the well-known side effects, such as UTI of the already available SGLT2 inhibitors, can be waived, a ROW deal will also be obvious in the near future. This would lead to a very rapid revaluation, whose course will only know one direction.